Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Alzheimer's Disease Target and a Potentially Broad Drug Discovery Approach

This article was originally published in Start Up

Executive Summary

Researchers have identified a new target in Alzheimer's disease--the natural substrate of an enzyme that itself has long been a target for AD drug development. That the molecule appears to be druggable is itself a surprising observation that may offer valuable insight into how to improve AD drugs. More than that, however, it suggests that substrates of protease inhibitors may provide a completely new set of drug targets in a variety of diseases.

You may also be interested in...



Antigen-Free Screening Finds Antibody Biomarkers For Alzheimer's Diagnosis

Use of a library of synthetic peptide-like molecules as a screen to identify disease-specific antibodies in serum has led to identification of biomarkers for Alzheimer's disease that could form the basis of a blood-based diagnostic test. The screening strategy may also be broadly applicable to the development of diagnostics for other diseases, for identifying antibody targets in autoimmune diseases, and even as the basis for vaccine development.

A New but Familiar Drug Target for Treating Memory Impairment

Inhibitors of histone deacetylases have been developed as cancer drugs, with only limited use because of toxicities. Now, a research team has shown that HDAC2 impairs memory and learning, suggesting that inhibitors targeting only that molecule could be used to treat neurodegenerative diseases. Buoyed by these new observations, companies with HDAC inhibitors in hand can screen their libraries specifically for activity against this newly-understood target.

Pfizer Goes Deeper Into Alzheimer’s Market With Medivation Deal

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel